Investors - Press Releases
<< Back |
View printer-friendly version |
TRHC’s MedWise Risk Score™ Reduces the Odds of Adverse Drug Events, Keeping Patients Safer
Article published in peer-reviewed Pharmacy showcases the power of TRHC’s multi-drug medication decision support tool
|
The research article is a 12-month analysis of medical claims data of 1,965 Program of All Inclusive Care for the Elderly (PACE ) participants by TRHC’s Precision Pharmacotherapy Research & Development Institute to determine their MedWise Risk Score™ (MRS). TRHC’s MedWise Risk Score™ helps identify those at highest risk for Adverse Drug Events (ADEs), requiring immediate medication management attention. Adverse Drug Events, if it were a disease, would be the third leading cause of death in
The study concludes that a significant positive correlation exists between the MRS and various outcomes, including emergency department visits, all-cause hospital admissions, and hospital length of stay. Each point increase in the MRS corresponds to
"I cannot imagine caring for frail elderly patients any longer without having access to this information,” said David Wensel DO, FAAHPM, HMDC, Chief Medical Officer at Midland Care, a Kansas PACE organization. “It has changed the way I prescribe medications and will soon be the standard of care for anyone caring for frail patients who take multiple medications. Using the MRS with the help of our clinical pharmacist, who is a valuable member of our interdisciplinary team, has certainly saved the lives of many of our patients."
“A majority of Adverse Drug Events are preventable,” states TRHC Chairman and CEO
In a 2018 study of PACE clinicians who use the MedWise Risk Score, 94% would recommend its use by pharmacists and physicians. In the same study, 84% believe that it helps them provide better care, in collaboration with their clinical pharmacist counterparts.
TRHC’s Medical Director
TRHC Chief Scientific Officer
About
Forward-Looking Statement
This press release includes forward-looking statements that we believe to be reasonable as of today’s date. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. These forward-looking statements include, among other things, our goals and expectations regarding the combined company and the integration of PW into TRHC, the expected synergies from the combined company and the expected financial and operating performance of TRHC following the completion of the acquisition. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the risk that we may not be able to achieve our expectations for the combined companies due to challenges in integration and inability to retain key employees; fluctuations in our financial results; the acceptance and use of our products and services by PACE organizations and pharmacies; the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; our ability to maintain relationships with a specified drug wholesaler; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; the requirements of being a public company; our ability to recognize the expected benefits from acquisitions on a timely basis or at all; and the other risk factors set forth from time to time in our filings with the
Media Contact abednar@trhc.com T: (856) 912-5714 |
Investors fsparacino@trhc.com T: (312) 451-2157 |
dsemingson@trhc.com T: (215) 870-0829 |
|
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4c975b20-6d60-4aa3-b6fc-be686d4ba1f9
Source: Tabula Rasa HealthCare, Inc.